Publisher
Springer Science and Business Media LLC
Reference4 articles.
1. Alvotech HF. Uzpruvo: EU summary of product characteristics; 2024. https://www.ema.europa.eu/en/documents/product-information/uzpruvo-epar-product-information_en.pdf. Accessed 4 June 2024.
2. European Medicines Agency. Uzpruvo (international non-proprietary name: ustekinumab): EU assessment report; 2024. https://www.ema.europa.eu/en/documents/assessment-report/uzprovo-epar-public-assessment-report_en.pdf. Accessed 4 June 2024.
3. Wynne C, Hamilton P, McLendon K, et al. A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults. Expert Opin Investig Drugs. 2023;32(5):417–27.
4. Feldman SR, Reznichenko N, Berti F, et al. Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis. Expert Opin Biol Ther. 2023;23(8):759–71.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献